Cargando…
SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
The pathogenesis of type 2 cardiorenal syndrome (CRS) is mostly associated with reduced cardiac output, increased central venous pressure (CVP), activation of the renin-angiotensin-aldosterone system (RAAS), inflammation, and oxidative stress. As a drug to treat diabetes, sodium-glucose transporter...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479647/ https://www.ncbi.nlm.nih.gov/pubmed/37674989 http://dx.doi.org/10.3389/fneph.2022.1109321 |
_version_ | 1785101637500534784 |
---|---|
author | Wang, Yajiao Mao, Xinxin Shi, Shuqing Xu, Xia Lv, Jiayu Zhang, Bingxuan Wu, Huaqin Song, Qingqiao |
author_facet | Wang, Yajiao Mao, Xinxin Shi, Shuqing Xu, Xia Lv, Jiayu Zhang, Bingxuan Wu, Huaqin Song, Qingqiao |
author_sort | Wang, Yajiao |
collection | PubMed |
description | The pathogenesis of type 2 cardiorenal syndrome (CRS) is mostly associated with reduced cardiac output, increased central venous pressure (CVP), activation of the renin-angiotensin-aldosterone system (RAAS), inflammation, and oxidative stress. As a drug to treat diabetes, sodium-glucose transporter 2 inhibitor (SGLT2i) has been gradually found to have a protective effect on the heart and kidney and has a certain therapeutic effect on CRS. In the process of chronic heart failure (CHF) leading to chronic renal insufficiency, the renal tubular system, as the main functional part of the kidney, is the first to be damaged, but this damage can be reversed. In this review, we focus on the protective mechanisms of SGLT2i targeting renal tubular in the treatment of CRS, including natriuresis and diuresis to relieve renal congestion, attenuate renal tubular fibrosis, improve energy metabolism of renal tubular, and slow tubular inflammation and oxidative stress. This may have beneficial effects on the treatment of CRS and is a direction for future research. |
format | Online Article Text |
id | pubmed-10479647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104796472023-09-06 SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules Wang, Yajiao Mao, Xinxin Shi, Shuqing Xu, Xia Lv, Jiayu Zhang, Bingxuan Wu, Huaqin Song, Qingqiao Front Nephrol Nephrology The pathogenesis of type 2 cardiorenal syndrome (CRS) is mostly associated with reduced cardiac output, increased central venous pressure (CVP), activation of the renin-angiotensin-aldosterone system (RAAS), inflammation, and oxidative stress. As a drug to treat diabetes, sodium-glucose transporter 2 inhibitor (SGLT2i) has been gradually found to have a protective effect on the heart and kidney and has a certain therapeutic effect on CRS. In the process of chronic heart failure (CHF) leading to chronic renal insufficiency, the renal tubular system, as the main functional part of the kidney, is the first to be damaged, but this damage can be reversed. In this review, we focus on the protective mechanisms of SGLT2i targeting renal tubular in the treatment of CRS, including natriuresis and diuresis to relieve renal congestion, attenuate renal tubular fibrosis, improve energy metabolism of renal tubular, and slow tubular inflammation and oxidative stress. This may have beneficial effects on the treatment of CRS and is a direction for future research. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC10479647/ /pubmed/37674989 http://dx.doi.org/10.3389/fneph.2022.1109321 Text en Copyright © 2023 Wang, Mao, Shi, Xu, Lv, Zhang, Wu and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nephrology Wang, Yajiao Mao, Xinxin Shi, Shuqing Xu, Xia Lv, Jiayu Zhang, Bingxuan Wu, Huaqin Song, Qingqiao SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title | SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title_full | SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title_fullStr | SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title_full_unstemmed | SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title_short | SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules |
title_sort | sglt2 inhibitors in the treatment of type 2 cardiorenal syndrome: focus on renal tubules |
topic | Nephrology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479647/ https://www.ncbi.nlm.nih.gov/pubmed/37674989 http://dx.doi.org/10.3389/fneph.2022.1109321 |
work_keys_str_mv | AT wangyajiao sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT maoxinxin sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT shishuqing sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT xuxia sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT lvjiayu sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT zhangbingxuan sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT wuhuaqin sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules AT songqingqiao sglt2inhibitorsinthetreatmentoftype2cardiorenalsyndromefocusonrenaltubules |